Cargando…

Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis

Complement factor C5a was originally identified as a powerful promoter of inflammation through activation of the C5a receptor 1 (C5ar1). Recent evidence suggests involvement of C5a not only in pro- but also in anti-inflammatory signaling. The present study aims to unveil the role of C5ar1 as potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommerfeld, Oliver, Medyukhina, Anna, Neugebauer, Sophie, Ghait, Mohamed, Ulferts, Svenja, Lupp, Amelie, König, Rainer, Wetzker, Reinhard, Schulz, Stefan, Figge, Marc Thilo, Bauer, Michael, Press, Adrian T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791006/
https://www.ncbi.nlm.nih.gov/pubmed/32966769
http://dx.doi.org/10.1016/j.ymthe.2020.09.008
_version_ 1783633520880517120
author Sommerfeld, Oliver
Medyukhina, Anna
Neugebauer, Sophie
Ghait, Mohamed
Ulferts, Svenja
Lupp, Amelie
König, Rainer
Wetzker, Reinhard
Schulz, Stefan
Figge, Marc Thilo
Bauer, Michael
Press, Adrian T.
author_facet Sommerfeld, Oliver
Medyukhina, Anna
Neugebauer, Sophie
Ghait, Mohamed
Ulferts, Svenja
Lupp, Amelie
König, Rainer
Wetzker, Reinhard
Schulz, Stefan
Figge, Marc Thilo
Bauer, Michael
Press, Adrian T.
author_sort Sommerfeld, Oliver
collection PubMed
description Complement factor C5a was originally identified as a powerful promoter of inflammation through activation of the C5a receptor 1 (C5ar1). Recent evidence suggests involvement of C5a not only in pro- but also in anti-inflammatory signaling. The present study aims to unveil the role of C5ar1 as potential therapeutic target in a murine sepsis model. Our study discloses a significantly increased survival in models of mild to moderate but not severe sepsis of C5ar1-deficient mice. The decreased mortality of C5ar1-deficient mice is accompanied by improved pathogen clearance and largely preserved liver function. C5ar1-deficient mice exhibited a significantly increased production of the pro-inflammatory mediator interferon-γ (IFN-γ) and a decreased production of the anti-inflammatory cytokine interleukin-10 (IL-10). Together, these data uncover C5a signaling as a mediator of immunosuppressive processes during sepsis and describe the C5ar1 and related changes of the IFN-γ to IL-10 ratio as markers for the immunological (dys)function accompanying sepsis.
format Online
Article
Text
id pubmed-7791006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-77910062022-01-06 Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis Sommerfeld, Oliver Medyukhina, Anna Neugebauer, Sophie Ghait, Mohamed Ulferts, Svenja Lupp, Amelie König, Rainer Wetzker, Reinhard Schulz, Stefan Figge, Marc Thilo Bauer, Michael Press, Adrian T. Mol Ther Original Article Complement factor C5a was originally identified as a powerful promoter of inflammation through activation of the C5a receptor 1 (C5ar1). Recent evidence suggests involvement of C5a not only in pro- but also in anti-inflammatory signaling. The present study aims to unveil the role of C5ar1 as potential therapeutic target in a murine sepsis model. Our study discloses a significantly increased survival in models of mild to moderate but not severe sepsis of C5ar1-deficient mice. The decreased mortality of C5ar1-deficient mice is accompanied by improved pathogen clearance and largely preserved liver function. C5ar1-deficient mice exhibited a significantly increased production of the pro-inflammatory mediator interferon-γ (IFN-γ) and a decreased production of the anti-inflammatory cytokine interleukin-10 (IL-10). Together, these data uncover C5a signaling as a mediator of immunosuppressive processes during sepsis and describe the C5ar1 and related changes of the IFN-γ to IL-10 ratio as markers for the immunological (dys)function accompanying sepsis. American Society of Gene & Cell Therapy 2021-01-06 2020-09-05 /pmc/articles/PMC7791006/ /pubmed/32966769 http://dx.doi.org/10.1016/j.ymthe.2020.09.008 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Sommerfeld, Oliver
Medyukhina, Anna
Neugebauer, Sophie
Ghait, Mohamed
Ulferts, Svenja
Lupp, Amelie
König, Rainer
Wetzker, Reinhard
Schulz, Stefan
Figge, Marc Thilo
Bauer, Michael
Press, Adrian T.
Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
title Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
title_full Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
title_fullStr Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
title_full_unstemmed Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
title_short Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
title_sort targeting complement c5a receptor 1 for the treatment of immunosuppression in sepsis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791006/
https://www.ncbi.nlm.nih.gov/pubmed/32966769
http://dx.doi.org/10.1016/j.ymthe.2020.09.008
work_keys_str_mv AT sommerfeldoliver targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT medyukhinaanna targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT neugebauersophie targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT ghaitmohamed targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT ulfertssvenja targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT luppamelie targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT konigrainer targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT wetzkerreinhard targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT schulzstefan targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT figgemarcthilo targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT bauermichael targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis
AT pressadriant targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis